Graph takes few seconds to load...
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases.
Its lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition.
Concert Pharmaceuticals has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
| Annual Data | Millions of US $ except per share data | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash on hand | $111.81 | $160.84 | $203.17 | $96.19 | $142.19 | - | - | - | - |
| Receivables | $0.07 | $0.02 | $0.16 | $0.03 | $0.25 | $1.28 | - | - | - |
| Inventory | - | - | $0 | $0 | $0 | $0 | - | - | - |
| Pre-Paid Expenses | - | - | - | - | - | - | - | - | - |
| Other Current Assets | $4.71 | $18.74 | $0 | $0 | $1.67 | $1.21 | $1.11 | $1.18 | $0.85 |
| Total Current Assets | $116.86 | $180.15 | $205.73 | $97.73 | $144.11 | $81.72 | - | - | - |
| Property, Plant, And Equipment | $17.01 | $8.92 | $2.17 | $2.20 | $2.35 | $2.28 | $2.47 | $3.45 | $4.44 |
| Long-Term Investments | $2.36 | $2.32 | $2.25 | - | - | - | - | - | - |
| Goodwill And Intangible Assets | - | - | $0 | $0 | $0 | $0 | - | - | - |
| Other Long-Term Assets | $3.61 | $3.48 | $3.84 | $0.47 | $0.48 | $0.45 | $3.26 | $0.83 | $0.83 |
| Total Long-Term Assets | $20.62 | $12.40 | $6 | $2.67 | $2.82 | - | - | - | - |
| Total Assets | $137.47 | $192.55 | $211.74 | $100.40 | $146.93 | $84.45 | $39.77 | $33.13 | $49.40 |
| Total Current Liabilities | $17.27 | $8.75 | $6.45 | $5.57 | $6.63 | $18.62 | $15.92 | $7.91 | $10.27 |
| Long Term Debt | - | - | $0 | $0 | $0 | $0 | $7.35 | $15.50 | $8.05 |
| Other Non-Current Liabilities | $2.75 | $16.06 | $8.86 | $9.23 | $9.67 | $11.01 | $16.37 | $4.56 | $6.34 |
| Total Long Term Liabilities | $18.75 | $16.06 | $8.86 | $9.23 | $9.67 | - | - | - | - |
| Total Liabilities | $36.01 | $24.81 | $15.30 | $14.80 | $16.30 | $29.63 | $39.63 | $27.97 | $24.66 |
| Common Stock Net | $0.02 | $0.02 | $0.02 | $0.02 | $0.02 | $0.02 | $0100000 | $0100000 | $0100000 |
| Retained Earnings (Accumulated Deficit) | $-194.68 | $-116.52 | $-76.24 | $-171.88 | $-121.16 | $-145.34 | - | - | - |
| Comprehensive Income | - | - | $0 | $0 | $0 | $0 | - | - | - |
| Other Share Holders Equity | $-0.03 | $-0.14 | $-0.41 | $-0700000 | $-0.02 | $-0.01 | - | - | - |
| Share Holder Equity | $101.46 | $167.74 | $196.43 | $85.59 | $130.64 | $54.83 | $0.14 | $5.16 | $24.74 |
| Total Liabilities And Share Holders Equity | $137.47 | $192.55 | $211.74 | $100.40 | $146.93 | - | - | - | - |
